Dr. Michael Jain, MD

• Hematology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Repeatability of metabolic tumor burden and lesion glycolysis between clinical readers, 2023-02-15

• Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma, 2021-12-06

• The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma, 2023-07-31

• Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells, 2019-06-18

• Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma, 2022-08-29

• Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy, 2021-07-06

• Outcomes of CD19 CAR T cell therapy in patients with gastrointestinal tract involvement of large B cell lymphoma, 2021-05-30

• Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy, 2021-04-01

• Change in neurocognitive performance among patients with non-Hodgkin's lymphoma in the first year after CAR T-cell therapy, 2022-04-01

• Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study Authors and Affiliation, 2023-04-01

• Cardiovascular Events Among Adults Treated with Chimeric Antigen Receptor T-Cells (CAR-T), 2019-12-24

• Change in patients' perceived cognition following chimeric antigen receptor T-cell therapy for lymphoma, 2022-05-14

• Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma, 2019-06-05